Can Aspirin Stop Liver Cancer in Hepatitis B Patients?11 months, 1 week ago
Posted on Nov 10, 2017, 4 p.m.
Daily aspirin may reduce the risk of liver cancer for people with hepatitis B infection, a new study suggests.
“Once again we find out that something simple and Preventative can help us lower risk. This is really the Anti-Aging Medicine Message that An Ounce of prevention is worth a pound of cure. I wrote an article about the benefits of Aspirin in 1982 in Life Extension, and Longevity News, and I have seen opinions swing back and forth over the years. However, I have always been sure than the research would pan out for long term benefits of Aspirin ,” said Dr. Ronald Klatz, President of the A4M, November 6, 2017.
(HealthDay News) -- Daily aspirin may reduce the risk of liver cancer for people with hepatitis B infection, a new study suggests.
Hepatitis B virus attacks the liver and can cause cirrhosis and liver cancer. Previous research suggests daily low-dose aspirin therapy may prevent cancer, but there is little clinical evidence on whether regular aspirin use can prevent liver cancer in people with hepatitis B.
Researchers from Taiwan analyzed data from close to 205,000 patients with chronic hepatitis B. They found that those on daily aspirin were much less likely to develop liver cancer over five years than those who did not take aspirin.
It's important to note, however, that the study only found these associations, but did not establish a cause-and-effect link.
The findings are scheduled to be presented Monday at an American Association for the Study of Liver Diseases meeting, in Washington, D.C.
About 240 million people worldwide have chronic hepatitis B, according to the association.
While antiviral medicines can significantly reduce liver cancer risk in people with the hepatitis B virus (HBV), they don't eliminate it and are not appropriate for everyone, said lead investigator Dr. Teng-Yu Lee.
Lee is a researcher in the department of gastroenterology at Taichung Veterans General Hospital.
"For effectively preventing HBV-related liver cancer, the findings of this study may help hepatologists treat patients with chronic HBV infection in the future, particularly for those who are not indicated for antiviral therapy. We are pursuing prospective investigations for further confirming the findings," Lee said in a meeting news release.
Research presented at medical meetings is typically considered preliminary until published in a peer-reviewed journal.
The U.S. Centers for Disease Control and Prevention has more on hepatitis B.
SOURCE: American Association for the Study of Liver Diseases, news release, Oct. 20, 2017
Copyright © 2017 HealthDay. All rights reserved.
Dr. Ronald Klatz, DO, MD President of the A4M has 28,000 Physician Members, has trained over 150,000 Physicians, health professionals and scientists in the new specialty of Anti-aging medicine. Estimates of their patients numbering in the 100’s of millions World Wide that are living better stronger, healthier and longer lives. www.WorldHealth.net